Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq on neuroblastoma PDX model COG-N-519 treated with control miR-1283 and test miR-99b-5p mimics

ABSTRACT: COG-N-519 primary neuroblastoma cells were innoculated by subcutaneous injection into NSG mice. When tumours reached a size of 100-200mm3 miRNAs conjugated to nanoparticles were injected intratumourally every 2 days for 1 week. 24 hr after the last injection, snap frozen tumour tissue was harvested for RNA extraction and RNA-seq analysis.

PROVIDER: EGAS00001005581 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq on neuroblastoma PDX model COG-N-519 treated with control miR-1283 and test miR-99b-5p mimics

Project description:COG-N-519 primary neuroblastoma cells were innoculated by subcutaneous injection into NSG mice. When tumours reached a size of 100-200mm3 miRNAs conjugated to nanoparticles were injected intratumourally every 2 days for 1 week. 24 hr after the last injection, snap frozen tumour tissue was harvested for RNA extraction and RNA-seq analysis.

| EGAS00001005368 | EGA

Next Generation Sequencing of Mantle cell lymphoma Granta-519 Transcriptomes

Project description:Purpose: The goal of this study is to get a deeper insight of whole transcriptome changes and of signaling pathways involved in eliciting the DPN-mediated effects on Granta-519 tumor progression in vivo. Methods: Mantle cell lymphoma cell line Granta-519 cells were grafted to male NSG mice, followed by treated with ESR2 selective agonist DPN or vehicle. When tumor size reached around 1300 mm3, RNA was extracted with RNeasy Plus Mini Kit (Qiagen) for sequencing. Results: ESR2 selective agonist DPN could inhibit cell adhesion, EMT and angiogenesis in vivo which likely involves regulation of VEGFA, FOS, FOSB, CXCR4, MALAT1 and NEAT1. Conclusions: Our study represents the detailed analysis of Granta-519 transcriptomes in vivo experiment after DPN treatment, with biologic replicates, generated by RNA-seq technology.

2022-07-01 | GSE190600 | GEO

MiR-16 and miR-519 suppress tumor cell proliferation in meningiomas via HuR inhibition

Project description:We investigated the relative expression levels of these miRs in a series of meningioma and normal meningeal tissues. The effects of miR-16 and miR-519 on cell growth and transcriptome were assessed in vitro using two human cell lines (Ben-Men-1 and IOMM-Lee). Both miR-16 and miR-519 were significantly downregulated in meningioma compared with normal meningeal tissue. Overexpression of either miR in IOMM-Lee and Ben-Men-1 cells significantly reduced cell growth. The transfection of miR-16 and miR-519 significantly downregulated HuR mRNA, and genes involved in various functions such as pre-replicative complex, mitotic recombination, S phase and M phase of cell cycle, and upregulated genes implicated in cell junction, and positive regulation of cell death. Cell-cycle-related genes associated cluster included HuR mRNA (ELAVL1), and was highly enriched with HuR gene targets.

2023-07-03 | GSE98848 | GEO

Gene expression analysis of JVM-2 and Granta-519 after CCDC50 gene modulation

Project description:Microarray-based gene expression analysis identified genes differentially expressed in JVM-2 and Granta-519 after CCDC50 gene modulation.

2010-06-03 | GSE16435 | GEO

Whole Genome Sequencing on OCIAML-22

Project description:Donor_OCIAML22_bulk: The donor (unsorted) that was used to generate OCI-AML22. OCI-AML22_bulk_1month_inVitro: The donor (unsorted) that was used to generate OCI-AML22 was expanded for 1 month in vitro, then sequenced. OCI-AML22_graft_CD34minus_WGS: The donor (unsorted) that was used to generate OCI-AML22 was expanded for 1 month in vitro, then injected in NSG-SGM3 mice. 21 weeks after injection, cells from 5 mice injected with 5 mice injected with 1475 cells per mice and 4 mice injected with 469 cells per mice were sorted. The human CD34- fraction was sequenced (CD45h+CD45m-7aad-annexinV-CD34-) OCI-AML22_graft_CD34positive_WGS: The donor (unsorted) that was used to generate OCI-AML22 was expanded for 1 month in vitro, then injected in NSG-SGM3 mice. 21 weeks after injection, cells from 5 mice injected with 5 mice injected with 1475 cells per mice and 4 mice injected with 469 cells per mice were sorted. The human CD34+ fraction was sequenced (CD45h+CD45m-7aad-annexinV-CD34+)

| EGAS00001006513 | EGA

Gene expression profile in tumor tissue in murine human lung cancer model between p-T-miR-7 and p-Cont injection group

Project description:Human lung cancer cell line 95D cells were injected subcutaneously into right flank of Balb/c nude mice (n=8). 7 days later, the plasmid of p-T-miR-7 (100mg) or p-Cont (100mg) was remote given by subcutaneous injection into the left flank of nude mice five times every three days. 3 days after last injection, tumor mass were collected. We sent the tumor tissue to Shanghai Kang Cheng company to detecte the cDNA chip in order to detect the gene expression in p-T-miR-7 injection group.

2016-12-13 | GSE92258 | GEO

Yersinia pestis strain:M-519

Project description:Yersinia pestis strain:M-519 Genome sequencing and assembly

| PRJNA307162 | ENA

Differentially expressed genes following injection with miR-1 mimics of the silkworm, Bombyx mori, during pupation

Project description:The molting of insects is a complex biological progress which requires varies of genes to participate in the event. MicroRNAs are considered to be one of the key roles involved in development in many organisms. Microarray technology was employed to examine the expression profile of multiple genes after extrinsical up-regulation of miR-1 level by injection of miR-1 mimics in silkworm (Bombyx mori.L), which caused altered expression profile of numerous genes, especially those which involved in the processes of cuticle renewing and development. 814 genes were up-regulated and 636 were down-regulated after treated with miR-1 mimics, the rest 2961 detectable genes were considered to have no significant changes in expression level. Transcription profiling experiments, 3 pairs of samples (miR-1 injected and negative control) were analyzed. Dual-channel experiments, with control samples labeled by Cy5 and miR-1 injected samples labeled by Cy3. Fold change was calculated via comparing signal intensity of Cy3 vs Cy5. 3 biological replicates were performed.

2012-02-25 | E-GEOD-36034 | biostudies-arrayexpress

Thinopyrum intermedium cultivar:C4-5353xC4-2856 519

Project description:Thinopyrum intermedium C4-5353xC4-2856 519 Population genome sequencing

| PRJNA368126 | ENA

AIDS Linked to the Intravenous Experience (ALIVE) Cohort

Project description:The AIDS Linked to the Intravenous Experience (ALIVE) Study is a long-standing community based research effort that includes past and current injection drug users (IDUs). ALIVE has been ongoing since 1988 and is one of the longest-running community-based cohorts of IDUs in existence. The primary objectives when the study started were to characterize the incidence and natural history of HIV among injection drug users (IDUs). At each study visit, participants undergo a series of questionnaires that elicit information about substance use (including drugs used and route of administration) and a blood draw. A subsample of 1200 subjects was selected for genotyping for the NIDA Smokescreen effort who report heroin injection and have existing peripheral blood samples (isolated buffy coat). In addition to injected heroin, ALIVE subjects are assessed on lifetime and previous six months use of marijuana (76.3%), crack (55.5%), snorted cocaine (48.3%), injected cocaine (89.9%), injected speedball (87.0%), and smoking heroin (9.0%). The sample is 33.4% female, ~85% African-American and assessed through a mean maximum age of 49.9 years old. Importantly, subjects are not assessed to meet DSM criteria, but all subjects report having injected drugs. We provide demographic data (age at assessment, sex, self-reported race) and drug use data (lifetime "use" ever endorsed) for each drug class/route described above for each subject

| phs001494 | dbGaP

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data